Tricida (NASDAQ:TCDAQ – Get Rating) is one of 993 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its peers? We will compare Tricida to related companies based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Profitability
This table compares Tricida and its peers' net margins, return on equity and return on assets.
Get Tricida alerts:| Net Margins | Return on Equity | Return on Assets | |
| Tricida | N/A | N/A | -103.81% |
| Tricida Competitors | -3,408.19% | -234.46% | -35.34% |
Institutional & Insider Ownership
40.7% of shares of all "Pharmaceutical preparations" companies are held by institutional investors. 35.6% of Tricida shares are held by company insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Tricida has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Tricida's peers have a beta of 0.91, indicating that their average stock price is 9% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Tricida and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tricida | 0 | 0 | 0 | 0 | N/A |
| Tricida Competitors | 4259 | 15158 | 41685 | 722 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 108.09%. Given Tricida's peers higher possible upside, analysts plainly believe Tricida has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares Tricida and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tricida | N/A | -$176.57 million | 0.00 |
| Tricida Competitors | $8.32 billion | $241.52 million | -3.90 |
Tricida's peers have higher revenue and earnings than Tricida. Tricida is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Tricida peers beat Tricida on 6 of the 10 factors compared.
About Tricida
(Get Rating)
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.